维普中文期刊产品整合服务

Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B,endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society

查看全文 作　　者：XIAOFEN [1]LIU;CHENRONG [2]HUANG;PHILLIP [3]JBERGEN;JIAN [3]LI;JINGJING [2]ZHANG;YIJIAN [1]CHEN;YONGCHUAN [4]CHEN;BEINING [1]GUO;FUPIN [1]HU;JINFANG [5]HU;LINLIN [6]HU;XIN [7]LI;HONGQIANG [8]QIU;HUA [6]SHAO;TONGWEN [9]SUN;YU [1]WANG;PING [10]XU;JING [9]YANG;YONG [11]YANG;ZHENWEI [12]YU;BIKUI [10]ZHANG;HUAIJUN [13]ZHU;XIAOCONG [14]ZUO;YI [15]ZHANG;LIYAN [2]MIAO;JING [1,16]ZHANG 高影响力作者 机构地区：[1]Institute of Antibiotics,Huashan Hospital,Fudan University/Key Laboratory of Clinical Pharmacology of Antibiotics,National Health Commission of the People's Republic of China/National Clinical Research Centre for Aging and Medicine,Huashan Hospital,Fudan University,Shanghai 200040,China;[2]Department of Clinical Pharmacology,the First Affiliated Hospital of Soochow University/Institute for Interdisciplinary Drug Research and Translational Sciences,College of Pharmaceutical Science,Soochow University,Suzhou 215000,China;[3]Biomedicine Discovery Institute and Department of Microbiology,Monash University,Melbourne,VIC 3800,Australia;[4]The Southwest Hospital of Army Medical University,Chongqing 400038,China;[5]The First Affiliated Hospital of Nanchang University,Nanchang 330006,China;[6]Zhongda Hospital Southeast University,Nanjing 210009,China;[7]The Third Hospital of Changsha,Changsha 410035,China;[8]Fujian Medical University Union Hospital,Fuzhou 350001,China;[9]The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;[10]The Second Xiangya Hospital of Central South University,Changsha 410011,China;[11]People's Hospital of Sichuan Province,Chengdu 610072,China;[12]Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University,Hangzhou 310020,China;[13]Nanjing Drum Tower Hospital,Nanjing 210008,China;[14]The Third Xiangya Hospital of Central South University,Changsha 430100,China;[15]Tianjin First Central Hospital,Tianjin 300190,China;[16]Research Ward of Huashan Hospital,Fudan University,Shanghai 200040,China高影响力机构 出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》索引2023年第24卷第2期,共13页高影响力期刊 基　　金：the Shanghai Leading Talents Award,Shanghai Municipal Health Commission(No.LJ2016-01);the Clinical Research Plan of Shanghai Hospital Development Center(No.SHDC2022CRW004)。 摘　　要：Polymyxin B,which is a last-line antibiotic for extensively drug-resistant Gram-negative bacterial infections,became available in China in Dec.2017.As dose adjustments are based solely on clinical experience of risk toxicity,treatment failure,and emergence of resistance,there is an urgent clinical need to perform therapeutic drug monitoring(TDM)to optimize the use of polymyxin B.It is thus necessary to standardize operating procedures to ensure the accuracy of TDM and provide evidence for their rational use.We report a consensus on TDM guidelines for polymyxin B,as endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society.The consensus panel was composed of clinicians,pharmacists,and microbiologists from different provinces in China and Australia who made recommendations regarding target concentrations,sample collection,reporting,and explanation of TDM results.The guidelines provide the first-ever consensus on conducting TDM of polymyxin B,and are intended to guide optimal clinical use. 关 键 词：Polymyxin B Therapeutic drug monitoring(TDM) PHARMACOKINETICS Clinical efficacy
相关文献

参考文献(76)

引证文献(13)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费